CRNX - Company ID 0001658247
The table below shows Crinetics Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$377.92M | -$230.19M | -$168.60M | -$115.20M | -$88.59M | -$62.03M |
| Capital expenditure | $5.76M | $3.84M | $4.69M | $1.66M | $436.00K | $186.00K |
| Investing cash flow | $173.91M | -$574.82M | -$200.41M | -$173.98M | -$56.48M | $217.00K |
| Dividends paid | - | - | - | - |
Crinetics Pharmaceuticals, Inc. reported operating cash flow of -$377.92M for fiscal year 2025. That is down 64.2% from -$230.19M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$5.47M (FY 2016) to -$377.92M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $40.61M | $1.01B | $391.24M | $121.96M | $252.68M | $114.57M |